In patients who have received neoadjuvant endocrine therapy for localized ER/PR+, HER2 negative breast cancer, how do you decide which patients to offer adjuvant chemotherapy to?   

What type of adjuvant chemotherapy would you offer?

Would clinically positive lymph nodes or residual disease at time of surgery change your decision?



Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at Siri Onclogy and hematology Infusion Service
Can you tell us what percentage of patients fit th...
Medical Oncologist at H Lee Moffitt Cancer Center, University of South Florida
In general, neoadjuvant endocrine therapy (NET) is...
Sign in or Register to read more